Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Net Income towards Common Stockholders data on file, last reported at -$576.0 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 304.98% year-over-year to -$576.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $696.0 million (up 516.77% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.58% from the prior year.
• Net Income towards Common Stockholders retreated to -$576.0 million in Q2 2026, from $370.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $519.0 million in Q1 2024 to a low of -$1.8 billion in Q4 2023.
• A 5-year average of -$290.5 million and a median of -$264.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 1286.59% — and 2024, when it surged 305.14%.
• Tracing TEVA's Net Income towards Common Stockholders over 5 years: stood at -$1.3 billion in 2022, then sank by 34.63% to -$1.8 billion in 2023, then surged by 84.69% to -$275.0 million in 2024, then jumped by 270.91% to $470.0 million in 2025, then tumbled by 222.55% to -$576.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$576.0 million (Q2 2026), $370.0 million (Q1 2026), and $470.0 million (Q4 2025), per Business Quant data.